 Emily Su
Concepts (223)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Placenta | 20 | 2025 | 787 | 5.060 |
Why?
| | Fetal Growth Retardation | 14 | 2025 | 593 | 4.900 |
Why?
| | Endothelial Cells | 10 | 2023 | 877 | 2.270 |
Why?
| | Estrogen Receptor beta | 6 | 2012 | 40 | 1.740 |
Why?
| | Umbilical Arteries | 3 | 2024 | 52 | 1.650 |
Why?
| | Neovascularization, Physiologic | 4 | 2021 | 193 | 1.510 |
Why?
| | Pregnancy | 35 | 2025 | 7215 | 1.320 |
Why?
| | Extracellular Matrix | 2 | 2025 | 562 | 1.160 |
Why?
| | Hypertension | 10 | 2025 | 1276 | 1.110 |
Why?
| | Hypertension, Pregnancy-Induced | 5 | 2024 | 69 | 1.080 |
Why?
| | Premature Birth | 6 | 2024 | 390 | 1.070 |
Why?
| | Pregnancy Complications, Cardiovascular | 8 | 2025 | 85 | 1.050 |
Why?
| | Aryl Hydrocarbon Receptor Nuclear Translocator | 2 | 2019 | 19 | 1.030 |
Why?
| | Antihypertensive Agents | 8 | 2025 | 521 | 0.990 |
Why?
| | Endometriosis | 6 | 2012 | 58 | 0.940 |
Why?
| | Chorionic Villi | 2 | 2024 | 25 | 0.840 |
Why?
| | Integrin alphaVbeta3 | 1 | 2022 | 20 | 0.750 |
Why?
| | Cell Movement | 4 | 2021 | 961 | 0.710 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 3 | 2022 | 74 | 0.680 |
Why?
| | Otoacoustic Emissions, Spontaneous | 1 | 2020 | 7 | 0.660 |
Why?
| | Acoustic Impedance Tests | 1 | 2020 | 13 | 0.660 |
Why?
| | Proteome | 1 | 2025 | 513 | 0.650 |
Why?
| | Prostaglandins | 2 | 2011 | 94 | 0.620 |
Why?
| | Neovascularization, Pathologic | 2 | 2019 | 287 | 0.620 |
Why?
| | Pre-Eclampsia | 6 | 2024 | 206 | 0.590 |
Why?
| | Progesterone | 4 | 2010 | 215 | 0.590 |
Why?
| | Proteomics | 2 | 2025 | 1188 | 0.590 |
Why?
| | Fetus | 5 | 2023 | 804 | 0.580 |
Why?
| | Estrogens | 2 | 2012 | 367 | 0.570 |
Why?
| | Artificial Intelligence | 1 | 2024 | 381 | 0.570 |
Why?
| | 17-Hydroxysteroid Dehydrogenases | 2 | 2010 | 4 | 0.570 |
Why?
| | Female | 47 | 2025 | 79035 | 0.530 |
Why?
| | Benzo(a)pyrene | 1 | 2016 | 8 | 0.480 |
Why?
| | Pregnancy Outcome | 7 | 2024 | 504 | 0.480 |
Why?
| | Cyclooxygenase 2 | 3 | 2016 | 167 | 0.470 |
Why?
| | Vascular Endothelial Growth Factor A | 6 | 2022 | 552 | 0.470 |
Why?
| | Receptors, Aryl Hydrocarbon | 1 | 2016 | 60 | 0.460 |
Why?
| | Endothelium, Vascular | 5 | 2018 | 956 | 0.460 |
Why?
| | Signal Transduction | 5 | 2019 | 5223 | 0.430 |
Why?
| | Endometrium | 4 | 2012 | 64 | 0.410 |
Why?
| | Stromal Cells | 4 | 2025 | 121 | 0.400 |
Why?
| | Humans | 48 | 2025 | 145763 | 0.400 |
Why?
| | Fibronectins | 2 | 2025 | 136 | 0.390 |
Why?
| | Reproduction | 2 | 2012 | 208 | 0.390 |
Why?
| | Umbilical Cord | 1 | 2013 | 93 | 0.370 |
Why?
| | Cell Proliferation | 2 | 2018 | 2514 | 0.370 |
Why?
| | Stillbirth | 1 | 2013 | 82 | 0.370 |
Why?
| | Fetal Diseases | 1 | 2013 | 194 | 0.330 |
Why?
| | Birth Weight | 4 | 2025 | 517 | 0.330 |
Why?
| | Endothelium | 1 | 2011 | 119 | 0.330 |
Why?
| | Infant, Newborn | 13 | 2025 | 6464 | 0.330 |
Why?
| | Ultrasonography, Doppler | 2 | 2024 | 126 | 0.300 |
Why?
| | Women's Health | 1 | 2012 | 316 | 0.300 |
Why?
| | Gene Expression Regulation, Enzymologic | 2 | 2007 | 267 | 0.290 |
Why?
| | Adult | 18 | 2025 | 40872 | 0.280 |
Why?
| | Estradiol | 3 | 2011 | 515 | 0.280 |
Why?
| | Promegestone | 1 | 2007 | 9 | 0.260 |
Why?
| | Infant, Small for Gestational Age | 2 | 2025 | 118 | 0.260 |
Why?
| | Postpartum Period | 3 | 2024 | 373 | 0.250 |
Why?
| | Up-Regulation | 3 | 2019 | 848 | 0.230 |
Why?
| | Estrogen Receptor alpha | 3 | 2012 | 151 | 0.230 |
Why?
| | Fetal Development | 2 | 2023 | 298 | 0.230 |
Why?
| | Dystonia | 1 | 2025 | 27 | 0.230 |
Why?
| | Pregnancy Trimester, Third | 1 | 2025 | 119 | 0.220 |
Why?
| | Chronic Disease | 7 | 2025 | 1812 | 0.220 |
Why?
| | Placental Circulation | 2 | 2017 | 71 | 0.210 |
Why?
| | Labetalol | 1 | 2024 | 6 | 0.210 |
Why?
| | Nifedipine | 1 | 2024 | 27 | 0.210 |
Why?
| | Case-Control Studies | 4 | 2021 | 3634 | 0.210 |
Why?
| | Hip Fractures | 1 | 2025 | 87 | 0.210 |
Why?
| | Hypotension | 1 | 2025 | 127 | 0.210 |
Why?
| | Uterus | 2 | 2017 | 228 | 0.200 |
Why?
| | Delivery, Obstetric | 1 | 2024 | 160 | 0.190 |
Why?
| | Breast Feeding | 2 | 2024 | 447 | 0.190 |
Why?
| | Integrin alpha5beta1 | 1 | 2022 | 9 | 0.190 |
Why?
| | Running | 1 | 2025 | 233 | 0.190 |
Why?
| | Cost of Illness | 1 | 2025 | 324 | 0.190 |
Why?
| | Gestational Age | 5 | 2024 | 989 | 0.190 |
Why?
| | Regional Blood Flow | 2 | 2017 | 514 | 0.180 |
Why?
| | Cells, Cultured | 5 | 2021 | 4151 | 0.180 |
Why?
| | Pregnancy in Diabetics | 1 | 2024 | 123 | 0.180 |
Why?
| | Epoprostenol | 2 | 2016 | 132 | 0.180 |
Why?
| | Extracellular Matrix Proteins | 1 | 2023 | 156 | 0.180 |
Why?
| | Cannabidiol | 1 | 2024 | 142 | 0.180 |
Why?
| | Dronabinol | 1 | 2024 | 249 | 0.170 |
Why?
| | Furin | 1 | 2021 | 12 | 0.170 |
Why?
| | Otoscopy | 1 | 2020 | 8 | 0.170 |
Why?
| | Trophoblasts | 2 | 2021 | 218 | 0.160 |
Why?
| | Receptors, Progesterone | 3 | 2012 | 244 | 0.160 |
Why?
| | Drug Monitoring | 1 | 2024 | 401 | 0.160 |
Why?
| | New Zealand | 1 | 2020 | 55 | 0.160 |
Why?
| | Receptors, Virus | 1 | 2021 | 95 | 0.160 |
Why?
| | Steroidogenic Factor 1 | 2 | 2012 | 13 | 0.160 |
Why?
| | Cellular Microenvironment | 1 | 2021 | 93 | 0.160 |
Why?
| | Serine Endopeptidases | 1 | 2021 | 129 | 0.160 |
Why?
| | Fibroblasts | 1 | 2025 | 1027 | 0.150 |
Why?
| | Cohort Studies | 4 | 2024 | 6032 | 0.150 |
Why?
| | Models, Biological | 2 | 2017 | 1764 | 0.150 |
Why?
| | RNA Interference | 3 | 2011 | 475 | 0.150 |
Why?
| | Parkinson Disease | 1 | 2025 | 601 | 0.140 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2018 | 86 | 0.140 |
Why?
| | Hypertension, Pulmonary | 2 | 2022 | 1957 | 0.140 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2024 | 655 | 0.130 |
Why?
| | Hospitalization | 2 | 2025 | 2460 | 0.130 |
Why?
| | Gene Expression Regulation | 3 | 2012 | 2601 | 0.130 |
Why?
| | Blood Pressure | 4 | 2025 | 1782 | 0.130 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2011 | 979 | 0.130 |
Why?
| | Fetal Blood | 2 | 2017 | 327 | 0.130 |
Why?
| | Research Design | 1 | 2023 | 1139 | 0.130 |
Why?
| | Feasibility Studies | 1 | 2020 | 1115 | 0.120 |
Why?
| | Mental Disorders | 1 | 2025 | 1169 | 0.120 |
Why?
| | Epigenesis, Genetic | 2 | 2012 | 693 | 0.120 |
Why?
| | Lab-On-A-Chip Devices | 1 | 2016 | 61 | 0.120 |
Why?
| | Substance-Related Disorders | 1 | 2025 | 1102 | 0.120 |
Why?
| | Maternal-Fetal Exchange | 1 | 2016 | 170 | 0.110 |
Why?
| | Cesarean Section | 3 | 2024 | 230 | 0.110 |
Why?
| | Blood Flow Velocity | 1 | 2015 | 421 | 0.100 |
Why?
| | Abruptio Placentae | 2 | 2024 | 6 | 0.100 |
Why?
| | Vascular Resistance | 1 | 2015 | 370 | 0.100 |
Why?
| | Growth Disorders | 1 | 2014 | 89 | 0.100 |
Why?
| | Infant, Premature | 2 | 2017 | 620 | 0.100 |
Why?
| | Fetal Distress | 1 | 2012 | 14 | 0.090 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2010 | 1450 | 0.090 |
Why?
| | Ovarian Diseases | 1 | 2012 | 14 | 0.090 |
Why?
| | Oogenesis | 1 | 2012 | 20 | 0.090 |
Why?
| | Ovulation | 1 | 2012 | 46 | 0.090 |
Why?
| | Estrogen Antagonists | 1 | 2012 | 37 | 0.090 |
Why?
| | Eicosanoids | 1 | 2012 | 58 | 0.090 |
Why?
| | Placentation | 1 | 2012 | 52 | 0.090 |
Why?
| | Pregnancy Proteins | 1 | 2012 | 36 | 0.090 |
Why?
| | Chorioamnionitis | 1 | 2012 | 50 | 0.090 |
Why?
| | Muscle Tonus | 1 | 2011 | 24 | 0.090 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 1 | 2011 | 76 | 0.090 |
Why?
| | Bronchopulmonary Dysplasia | 1 | 2017 | 420 | 0.090 |
Why?
| | Parturition | 1 | 2012 | 69 | 0.080 |
Why?
| | Retrospective Studies | 3 | 2025 | 17325 | 0.080 |
Why?
| | Metabolic Networks and Pathways | 1 | 2012 | 175 | 0.080 |
Why?
| | Ultrasonography | 1 | 2015 | 788 | 0.080 |
Why?
| | Large Neutral Amino Acid-Transporter 1 | 1 | 2010 | 17 | 0.080 |
Why?
| | Vasoconstriction | 1 | 2011 | 216 | 0.080 |
Why?
| | Myometrium | 1 | 2010 | 38 | 0.080 |
Why?
| | Placenta Growth Factor | 2 | 2022 | 26 | 0.080 |
Why?
| | Leiomyoma | 1 | 2010 | 61 | 0.080 |
Why?
| | Apoptosis | 1 | 2018 | 2443 | 0.080 |
Why?
| | Prospective Studies | 4 | 2024 | 8075 | 0.080 |
Why?
| | Child, Preschool | 2 | 2024 | 11868 | 0.070 |
Why?
| | Paracrine Communication | 1 | 2010 | 67 | 0.070 |
Why?
| | Thromboxanes | 1 | 2009 | 14 | 0.070 |
Why?
| | Uterine Neoplasms | 1 | 2010 | 98 | 0.070 |
Why?
| | Blotting, Western | 1 | 2011 | 1184 | 0.070 |
Why?
| | Neoplasm Proteins | 1 | 2012 | 442 | 0.070 |
Why?
| | Molecular Targeted Therapy | 1 | 2012 | 440 | 0.070 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2010 | 271 | 0.070 |
Why?
| | Vasodilation | 1 | 2011 | 521 | 0.070 |
Why?
| | Glucocorticoids | 1 | 2012 | 532 | 0.070 |
Why?
| | Retinoid X Receptor alpha | 1 | 2007 | 3 | 0.070 |
Why?
| | Progesterone Congeners | 1 | 2007 | 8 | 0.070 |
Why?
| | Retinoic Acid Receptor alpha | 1 | 2007 | 16 | 0.060 |
Why?
| | Receptors, Retinoic Acid | 1 | 2007 | 44 | 0.060 |
Why?
| | Immunohistochemistry | 1 | 2011 | 1723 | 0.060 |
Why?
| | Aromatase | 1 | 2007 | 37 | 0.060 |
Why?
| | Promoter Regions, Genetic | 1 | 2012 | 1247 | 0.060 |
Why?
| | Immunoblotting | 1 | 2007 | 295 | 0.060 |
Why?
| | Breast Neoplasms | 2 | 2012 | 2393 | 0.060 |
Why?
| | Fluorescent Antibody Technique | 1 | 2007 | 365 | 0.060 |
Why?
| | Databases, Factual | 1 | 2011 | 1491 | 0.060 |
Why?
| | Animals | 4 | 2012 | 38097 | 0.060 |
Why?
| | Endometrial Neoplasms | 1 | 2007 | 205 | 0.050 |
Why?
| | Arterial Pressure | 1 | 2024 | 134 | 0.050 |
Why?
| | RNA, Messenger | 2 | 2010 | 2805 | 0.050 |
Why?
| | Biomarkers | 3 | 2022 | 4302 | 0.050 |
Why?
| | Male | 6 | 2025 | 73003 | 0.050 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 2022 | 78 | 0.040 |
Why?
| | Triage | 1 | 2024 | 250 | 0.040 |
Why?
| | Cell Differentiation | 1 | 2010 | 2050 | 0.040 |
Why?
| | Fetal Hypoxia | 1 | 2022 | 56 | 0.040 |
Why?
| | Administration, Oral | 1 | 2024 | 867 | 0.040 |
Why?
| | Virus Internalization | 1 | 2021 | 65 | 0.040 |
Why?
| | Ovarian Neoplasms | 1 | 2007 | 595 | 0.040 |
Why?
| | Middle Aged | 4 | 2025 | 36302 | 0.040 |
Why?
| | Child Development | 1 | 2024 | 483 | 0.040 |
Why?
| | Length of Stay | 1 | 2025 | 1350 | 0.040 |
Why?
| | Prevalence | 1 | 2025 | 2874 | 0.030 |
Why?
| | Altitude | 1 | 2022 | 463 | 0.030 |
Why?
| | Patient Acceptance of Health Care | 1 | 2024 | 883 | 0.030 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2017 | 90 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2022 | 2123 | 0.030 |
Why?
| | Microvilli | 1 | 2016 | 75 | 0.030 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2021 | 440 | 0.030 |
Why?
| | Infant, Extremely Premature | 1 | 2017 | 68 | 0.030 |
Why?
| | Proof of Concept Study | 1 | 2016 | 89 | 0.030 |
Why?
| | Body Mass Index | 1 | 2024 | 2447 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2016 | 247 | 0.030 |
Why?
| | Microscopy, Confocal | 1 | 2016 | 319 | 0.030 |
Why?
| | United States | 2 | 2025 | 16123 | 0.030 |
Why?
| | Aged | 2 | 2025 | 26215 | 0.030 |
Why?
| | Equipment Design | 1 | 2016 | 525 | 0.030 |
Why?
| | Adolescent | 1 | 2013 | 22573 | 0.020 |
Why?
| | Time Factors | 1 | 2024 | 7133 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2025 | 8346 | 0.020 |
Why?
| | Cardiotocography | 1 | 2012 | 5 | 0.020 |
Why?
| | Fetal Monitoring | 1 | 2012 | 20 | 0.020 |
Why?
| | Young Adult | 2 | 2024 | 14251 | 0.020 |
Why?
| | Heart Rate, Fetal | 1 | 2012 | 31 | 0.020 |
Why?
| | Mice | 1 | 2010 | 18355 | 0.020 |
Why?
| | Emergency Service, Hospital | 1 | 2024 | 2383 | 0.020 |
Why?
| | Microarray Analysis | 1 | 2012 | 117 | 0.020 |
Why?
| | Cell Line | 1 | 2016 | 2823 | 0.020 |
Why?
| | Mifepristone | 1 | 2010 | 54 | 0.020 |
Why?
| | Hormone Antagonists | 1 | 2010 | 33 | 0.020 |
Why?
| | Infant | 1 | 2024 | 10090 | 0.020 |
Why?
| | CpG Islands | 1 | 2010 | 171 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2024 | 11793 | 0.020 |
Why?
| | Acute Disease | 1 | 2012 | 1036 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2017 | 2967 | 0.020 |
Why?
| | Dinoprostone | 1 | 2008 | 180 | 0.020 |
Why?
| | Cell Survival | 1 | 2010 | 1103 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2010 | 2028 | 0.010 |
Why?
| | Gene Expression Profiling | 1 | 2012 | 1777 | 0.010 |
Why?
| | DNA Methylation | 1 | 2010 | 690 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2012 | 2933 | 0.010 |
Why?
| | Transcription Factors | 1 | 2008 | 1736 | 0.010 |
Why?
| | Inflammation | 1 | 2008 | 2883 | 0.010 |
Why?
|
|
Su's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|